[an error occurred while processing this directive] | [an error occurred while processing this directive]
Therapeutic value of thoracic radiotherapy in elderly patients with extensive-stage small cell lung cancer
Qi Jing, Xu Liming, Luo Jing, Sun Jian, Wang Xin, Zhao Lujun
Department of Radiation Oncology,Tianjin Medical University Cancer Institute and Hospital;Key Laboratory of Cancer Prevention and Therapy;National Clinical Research Center for Cancer;Tianjin′s Clinical Research Center for Cancer, Tianjin 300060,China
AbstractObjective To evaluate the effect of thoracic radiotherapy (TRT) on the prognosis of elderly patients with extensive-stage small cell lung cancer (ES-SCLC). Methods Clinical data of 83 patients aged≥65 years diagnosed with metastatic ES-SCLC admitted to our hospital from 2010 to 2016 were retrospectively analyzed. All enrolled patients received etoposide plus cisplatin or carboplatin as the standard regimen for chemotherapy. After the propensity score matching (PSM), 70 cases were either assigned into the TRT (n=35) or non-TRT groups (n=35). Among them, 56 patients were male and 14 female. The median age was 69 years (range:65-85 years). The median chemotherapy cycle was 4 cycles (range:1-11 cycles). The median chest irradiation dose was 50 Gy (range:30-60 Gy). Overall survival (OS), progression-free survival (PFS) and local recurrence-free survival (LRFS) were regarded as end-point of observation. The survival rate was calculated by using Kaplan-Meier method and statistically compared between two groups by using Log-rank test. Multivariate prognostic analysis was performed using Cox regression model. Results For all patients, the 1-year OS, PFS and LRFS rates were 40%, 16% and 21%, respectively. Patients undergoing TRT obtained better survival outcomes than their counterparts without TRT:the 1-year OS, PFS and LRFS were 52% vs.29%(P=0.005), 30% vs.3%(P<0.001), 38% vs. 6%(P<0.001), respectively. Furthermore, TRT did not increase the incidence of adverse reactions in elderly patients (P=0.690). Conclusion The addition of TRT for elder ES-SCLC patients can significantly improve the rate of chest tumor control and prolong the survival time, which is worthy of further validation by prospective studies with large sample size.
Qi Jing,Xu Liming,Luo Jing et al. Therapeutic value of thoracic radiotherapy in elderly patients with extensive-stage small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2019, 28(7): 499-504.
Qi Jing,Xu Liming,Luo Jing et al. Therapeutic value of thoracic radiotherapy in elderly patients with extensive-stage small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2019, 28(7): 499-504.
[1]Jemal A. Cancer statistics,2016.[J]. CA-Cancer J Clin,2013,63(1):11. DOI:10.3322/caac.21332. [2]Rossi A,Maione P,Colantuoni G,et al. Treatment of small cell lung cancer in the elderly[J]. Oncologist,2005,42(1):399-411. DOI:10.1634/theoncologist.10-6-399. [3]Pujol JL,Carestia L,Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent[J]. Br J Cancer,2000,83(1):8-15. DOI:10.1054/bjoc.2000.1164. [4]Eckert F,Muller AC. SCLC extensive disease—treatment guidance by extent or/and biology of response?[J]. Radiat Oncol,2008,3(1):33. DOI:10.1186/1748-717X-3-33. [5]Slotman BJ,Faivre-Finn C,Tinteren HV,et al. International multicenter randomized study on thoracic radiation therapy (RT) in extensive stage small cell lung cancer (ES-SCLC):patterns of disease recurrence[J]. Int J Radiat Oncol Biol Phys,2014,90(1):S3-S4. DOI:10.1016/j.ijrobp.2014.06.023. [6]Slotman BJ,Faivrefinn C,Van Tinteren H,et al. Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer[J]. J Clin Oncol,2014.32 Suppl:abstr 7502. [7]Eskandar A,Ahmed A,Daughtey M,et al. Racial and sex differences in presentation and outcomes of small cell lung cancer in the United States:1973 to 2010[J]. Chest,2015,147(4):e164-e165. DOI:10.1378/chest.14-3051. [8]Xu LM,Cheng C,Kang M,et al. Thoracic radiotherapy (TRT) improved survival in both oligo-and polymetastatic extensive stage small cell lung cancer[J]. Sci Rep,2017,7(1):9255. DOI:10.1038/s41598-017-09775-0. [9]陈筱玲,方健,聂鋆,等.160例老年小细胞肺癌预后多因素分析[J]. 中国肺癌杂志,2014(1):15-23. DOI:10.3779/j.issn.1009-3419.2014.01.03. Chen XL,Fang J,Nie J,et al. Multivariate analysis of prognostic factors in the elderly patients with small cell lung cancer:a study of 160 patients[J]. Clin J of Lung Cancer,2014,17(1):15-23. DOI:10.3779/j.issn.1009-3419.2014.01.03. [10]刘天星,董玫,张永敏.65岁以上非小细胞肺癌三维适形放射治疗的疗效观察[J]. 中国肺癌杂志,2006,9(5):462-464. DOI:10.3779/j.issn.1009-3419.2006.05.16. Liu TX,Dong M,Zhang YM. Therapeutic effect of three dimensional conformal radiotherapy in patients aged 65 years and older with non-small cell lung cancer[J]. J Chin Lung,2006,9(5):462-464. DOI:10.3779/j.issn.1009-3419.2006.05.16. [11]Schiller JH,Adak S,Cella D,et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer:E7593-a phase Ⅲ trial of the Eastern Cooperative Oncology Group[J]. J Clin Oncol,2001,19(8):2114-2122. DOI:10.1200/JCO.2001.19.8.2114. [12]Giaccone G,Dalesio O,McVie GJ,et al. Maintenance chemotherapy in small-cell lung cancer:long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group[J]. J Clin Oncol,1993,11(7):1230-1240. DOI:10.1200/JCO.1993.11.7.1230. [13]Sculier JP,Paesmans M,Bureau G,et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party[J]. J Clin Oncol,1996,14(8):2337-2344. DOI:10.1200/JCO.1996.14.8.2337. [14]Lara PJ,Natale R,Crowley J,et al. Phase Ⅲ trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer:clinical and pharmacogenomic results from SWOG S0124[J]. J Clin Oncol,2009,27(15):2530-2535. DOI:10.1200/JCO.2008.20.1061. [15]Noda K,Nishiwaki Y,Kawahara M,et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer[J]. N Engl J Med,2002,346(2):85-91. DOI:10.1056/NEJMoa003034. [16]Niell HB,Herndon JN,Miller AA,et al. Randomized phase Ⅲ intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer:Cancer and Leukemia Group B Trial 9732[J]. J Clin Oncol,2005,23(16):3752-3759. DOI:10.1200/JCO.2005.09.071. [17]Pietanza MC,Kadota K,Huberman K,et al. Phase Ⅱ trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer,with assessment of methylguanine-DNA methyltransferase as a potential biomarker[J]. Clin Cancer Res,2012,18(4):1138-1145. DOI:10.1158/1078-0432. CCR-11-2059. [18]von Pawel J,Jotte R,Spigel DR,et al. Randomized phase Ⅲ trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer[J]. J Clin Oncol,2014,32(35):4012-4019. DOI:10.1200/JCO.2013.54.5392. [19]Peifer M,Fernandez-Cuesta L,Sos ML,et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer[J]. Nat Genet,2012,44(10):1104-1110. DOI:10.1038/ng.2396. [20]Fichtner I,Rolff J,Soong R,et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers[J]. Clin Cancer Res,2008,14(20):6456-6468. DOI:10.1158/1078-0432. CCR-08-0138. [21]Hou JM,Krebs MG,Lancashire L,et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer[J]. J Clin Oncol,2012,30(5):525-532. DOI:10.1200/JCO.2010.33.3716. [22]Jahchan NS,Dudley JT,Mazur PK,et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors[J]. Cancer Discov,2013,3(12):1364-1377. DOI:10.1158/2159-8290. CD-13-0183. [23]Jalal SI,Lavin P,Lo G,et al. Carboplatin and etoposide with or without palifosfamide in untreated extensive-stage small-Cell lung cancer:a multicenter,adaptive,randomized phase Ⅲ study (MATISSE)[J]. J Clin Oncol,2017,35(23):2619-2623. DOI:10.1200/JCO.2016.71.7454. [24]Glisson B,Besse B,Dols MC,et al. A Randomized,placebo-controlled,phase 1b/2 study of rilotumumab or ganitumab in combination with platinum-based chemotherapy as first-line treatment for extensive-stage small-cell lung cancer[J]. Clin Lung Cancer,2017,18(6):615-625. DOI:10.1016/j.cllc.2017.05.007. [25]Sanborn RE,Patel JD,Masters GA,et al. A randomized,double-blind,phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer:hoosier cancer research network LUN06-113[J]. Cancer,2017,123(2):303-311. DOI:10.1002/cncr.30287. [26]Socinski MA,Kaye FJ,Spigel DR,et al. Phase 1/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease[J]. Clin Lung Cancer,2017,18(1):68-76. DOI:10.1016/j.cllc.2016.09.002. [27]Reck M,Luft A,Szczesna A,et al. Phase Ⅲ randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer[J]. J Clin Oncol,2016,34(31):3740-3748. DOI:10.1200/JCO.2016.67.6601. [28]Antonia SJ,Lopez-Martin JA,Bendell J,et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032):a multicentre,open-label,phase 1/2 trial[J]. Lancet Oncol,2016,17(7):883-895. DOI:10.1016/S1470-2045(16)30098-5. [29]Slotman BJ,Faivre-Finn C,van Tinteren H,et al. Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy:a secondary analysis of the phase Ⅲ CREST trial[J]. Lung Cancer,2017,108:150-153. DOI:10.1016/j.lungcan.2017.03.007. [30]Gore EM,Hu C,Sun AY,et al. Randomized Phase Ⅱ study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC):NRG Oncology RTOG 0937[J]. J Thorac Oncol,2017,12(10):1561-1570. DOI:10.1016/j.jtho.2017.06.015. [31]Ershler WB,Longo DL. Aging and cancer:issues of basic and clinical science[J]. J Natl Cancer Inst,1997,89(20):1489-1497. DOI:10.1093/jnci/89.20.1489. [32]An C,Jing W,Zhang Y,et al. Thoracic radiation therapy could give survival benefit to elderly patients with extensive-stage small-cell lung cancer[J]. Future Oncol,2017,13(13):1149-1158. DOI:10.2217/fon-2016-0467.
2019, Vol. 28 
